Medpace Holdings, Inc. Stock price

Equities

MEDP

US58506Q1094

Biotechnology & Medical Research

Market Closed - Nasdaq 04:00:00 2024-02-09 pm EST 5-day change 1st Jan Change
326.4 USD +2.50% Intraday chart for Medpace Holdings, Inc. +10.40% +6.48%
Sales 2023 * 1.89B Sales 2024 * 2.18B Capitalization 10.01B
Net income 2023 * 275M Net income 2024 * 317M EV / Sales 2023 * 5.22 x
Net cash position 2023 * 166M Net cash position 2024 * 472M EV / Sales 2024 * 4.38 x
P/E ratio 2023 *
37.8 x
P/E ratio 2024 *
32.8 x
Employees 5,800
Yield 2023 *
-
Yield 2024 *
-
Free-Float 78.83%
More Fundamentals * Assessed data
Dynamic Chart
1 day+2.50%
1 week+10.40%
Current month+11.94%
1 month+13.74%
3 months+18.53%
6 months+21.95%
Current year+6.48%
More quotes
1 week
291.15
Extreme 291.15
331.10
1 month
277.72
Extreme 277.72
331.10
Current year
277.72
Extreme 277.72
331.10
1 year
167.00
Extreme 167
331.10
3 years
126.95
Extreme 126.945
331.10
5 years
50.14
Extreme 50.14
331.10
10 years
21.76
Extreme 21.76
331.10
More quotes
Managers TitleAgeSince
Chief Executive Officer 67 92-06-30
Director of Finance/CFO 50 18-10-31
President 50 07-09-30
Members of the board TitleAgeSince
Director/Board Member 72 18-08-12
Chief Executive Officer 67 92-06-30
Director/Board Member 64 18-08-12
More insiders
Date Price Change Volume
24-02-09 326.4 +2.50% 364,488
24-02-08 318.4 +3.13% 273,098
24-02-07 308.8 +2.04% 245,405
24-02-06 302.6 +2.47% 132,080
24-02-05 295.3 -0.12% 131,151

Delayed Quote Nasdaq, February 09, 2024 at 04:00 pm EST

More quotes
Medpace Holdings, Inc. is a global provider of clinical research-based drug and medical device development services. The Company is focused on providing scientifically driven outsourced clinical development services to the biotechnology, pharmaceutical and medical device industries. The Company partners with pharmaceutical, biotechnology, and medical device companies in the development and execution of clinical trials. The Company's drug development services focuses on full-service Phase I-IV clinical development services and include development plan design, coordinated central laboratory, project management, regulatory affairs, clinical monitoring, data management and analysis, pharmacovigilance new drug application submissions, and post-marketing clinical support. It also provides bio-analytical laboratory services, clinical human pharmacology, imaging services, and electrocardiography reading support for clinical trials. Its operations are based in North America, Europe, and Asia.
Calendar
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
C+
More Ratings
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
6
Last Close Price
326.4 USD
Average target price
283.2 USD
Spread / Average Target
-13.23%
Consensus
  1. Stock
  2. Equities
  3. Stock Medpace Holdings, Inc. - Nasdaq
+229% on MICROSOFT CORPORATION since our purchase on January 11, 2019
Replicate our performance
fermer